Metformin (MET) can be an alternative therapeutic strategy for managing ocular burn primarily because of its pleiotropic mechanism. Longer retention on the ocular surface and sustained release are necessary to ensure the efficacy of MET for ocular application. Although the high aqueous solubility of MET is good for formulation and biocompatibility, it makes MET prone to high nasolacrimal drainage. This limits ocular residence and may be a challenge in its application. To address this, polymers approved for ophthalmic application with natural origin were analyzed through in silico methods to determine their ability to bind to mucin and interact with MET. An ocular insert of MET (3 mg/6 mm) was developed using a scalable solvent casting method without using preservatives. The relative composition of the insert was 58 ± 2.06 %w/w MET with approximately 14 %w/w tamarind seed polysaccharide (TSP), and 28 %w/w propylene glycol (PG). Its stability was demonstrated as per the ICH Q1A (R2) guidelines. Compatibility, ocular retention, drug release, and other functional parameters were evaluated. In rabbits, efficacy was demonstrated in the 'corneal alkali burn preclinical model'. TSP showed potential for mucoadhesion and interaction with MET. With adequate stability and sterility, the insert contributed to adequate retention of MET (10-12 h) in vivo and slow release (30 h) in vitro. This resulted in significant efficacy in vivo.
Delayed-Action Preparations , Drug Liberation , Eye Burns , Metformin , Polysaccharides , Seeds , Tamarindus , Animals , Metformin/chemistry , Metformin/administration & dosage , Rabbits , Tamarindus/chemistry , Polysaccharides/chemistry , Seeds/chemistry , Eye Burns/drug therapy , Eye Burns/chemically induced , Administration, Ophthalmic , Drug Implants , Male , Burns, Chemical/drug therapy , Drug Stability , Corneal Injuries/drug therapy , Cornea/metabolism , Cornea/drug effects , Propylene Glycol/chemistry , Solubility
